by Charles D. Burger, MD; Steven D. Nathan, MD; and Justin Oldham, MD, MS
Treatment of fibrosis and pulmonary vascular disease is ripe for improvement. Our featured experts consider recent investigative work, looking forw......READ MORE
by Charles D. Burger, MD; Steven D. Nathan, MD; and Justin Oldham, MD, MS
Clinicians face multiple obstacles and challenges to the early diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), including its simila......READ MORE
Pulmonary hypertension (PH) and other comorbidities that reduce exercise tolerance have been shown to reduce survival among patients with interstit......READ MORE
Multiple superimposed processes and comorbidities may contribute to respiratory decline in patients with combined pulmonary fibrosis and emphysema ......READ MORE
Outcomes in patients with chronic lung disease may have one or more drivers of greater relative importance, such as lung parenchymal/fibrotic disea......READ MORE
An important subset of patients with fibrotic interstitial lung disease (ILD) experience a decline in lung function with progressive symptoms and p......READ MORE
